Editorial on immune checkpoint inhibitors in the treatment of hepatocellular carcinoma

Immunomodulatory effect of locoregional therapy in the tumor microenvironment

(2023) Lin Xie et al.   MOLECULAR THERAPY

Radiation therapy in the era of immune treatment for hepatocellular carcinoma

(2023) Lingjuan Chen et al.   Frontiers in Immunology

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

(2022) Ahmed Omar Kaseb et al.   Lancet Gastroenterology & Hepatology

Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma

(2022) Stefania De Lorenzo et al.   Cancers

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Gastroenterology & Hepatology

Resistance mechanisms to checkpoint inhibitors

(2021) Sarah A Weiss et al.   CURRENT OPINION IN IMMUNOLOGY

Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations

(2021) Xiao-Dong Zhu et al.   Liver Cancer

CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis

(2021) Masatoshi Kudo et al.   JOURNAL OF HEPATOLOGY

Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients

(2021) Wenwen Zhang et al.   Frontiers in Oncology

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

(2021) Maria Reig et al.   JOURNAL OF HEPATOLOGY

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?

(2020) Rossana Franzin et al.   Frontiers in Immunology

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Liver immunology and its role in inflammation and homeostasis

(2016) Mark W Robinson et al.   Cellular & Molecular Immunology

Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma

(2016) David Friedman et al.   HEPATOLOGY RESEARCH